Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the ...
Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope. The combination of amivantamab and lazertinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback